Current progress in structure-based rational drug design marks a new mindset in drug discovery

Computational and Structural Biotechnology Journal

Volumn 5, Issue 6, 2013, Pages e201302011-

  Lounnas, Valère ^a   Ritschel, Tina ^b   Kelder, Jan ^c   McGuire, Ross ^d   Bywater, Robert P ^e   Foloppe, Nicolas ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c BioAxis Research BV ^*  (United Kingdom)

^d BioAxis Research BV   (Netherlands)

^e MAGDALEN COLLEGE   (United Kingdom)

Author keywords

G protein coupled receptors; Ligand binding thermodynamics; Protein kinase; Rational drug design; Virtual screening

Indexed keywords

EID: 84884657202     PISSN: None     EISSN: 20010370     Source Type: Journal    
DOI: 10.5936/csbj.201302011     Document Type: Short Survey

References (162)

1. Szollosi-Janze M (2001) Science in the Third Reich (German Historical Perspectives). Oxford, UK: Berg Publishers. 256 p.
2. Murray GR (1920) The life history of the first case of myxoedema treated by thyroid extract. Br Med J 1920: 359-360.
3. Wolf G (2004) The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 134: 1299-1302. (Pubitemid 38720697)
4. Hansen SE (2008) The development of adrenal cortical hormones into drugs. Dan MedidnhistArbcg 36: 109-132.
5. Rosenheim O, King H (1932) The Ring-system of sterols and bile acids. Part II. J Chem Technol Biotechnol 51: 954-957.
6. Ingle DJ (1950) The biologic properties of cortisone: a review. J Clin Endocrinol Metab 10: 1312-1354.
7. Stouch TR (2012) The errors of our ways: taking account of error in computer-aided drug design to build confidence intervals for our next 25 years. J Comput Aided Mol Des 26: 125-134.
8. Marshall GR (2012) Limiting assumptions in structure-based design: binding entropy. J Comput Aided Mol Des 26: 3-8.
9. Craig A (2003) Astronomers count the stars. Available: http://news.bbc.co.Uk/2/hi/science/nature/3085885.stm. Accessed 2013 Jan 25.
10. Reymond JL, Blum LC, van Deursen R (2011) Exploring the chemical space of known and unknown organic small molecules at www.gdb.unibe.ch. Chimia (Aarau) 65: 863-867.
11. Gorse AD (2006) Diversity in medicinal chemistry space. Curr Top Med Chem 6: 3-18.
12. Rubenstein K, Coty C High Throughput Screening: Redefining the Mission. Available:http://pharmalicensing.com/public/articles/view/100556 8086-3befc0562a952/. Accessed 2013 Jan 25.
13. Rick Mullin (2004) Drug Discovery: As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chemical & Engineering News 82: 23-32..
14. Hopkins AL, Groom CR, Alex A (2004) Ligand efficiency: a useful metric for lead selection Drug Discovery Today 9: 430-431. (Pubitemid 38510559)
15. Vicki Glaser (2009) High Throughput Screening Retools for the Future. Available: http://www.bioitworld.com/BioIT-Article.aspx?id=86836. Accessed 2013 Jan 25.
16. Miteva MA (2008) Hierarchical structure-based virtual screening for drug design. Biotechnol & Biotechnol Equip 1: 634-638.
17. Miteva MA, Olivier Sperandio, Bruno O. Villoutreix (2007) Virtual Ligand Screening for Structure-based Drug Design: Approaches and Progress. Bioautomation 7: 104 - 121.
18. Foloppe N, Fisher LM, Howes R, Potter A, Robertson AGS, Surgenor AE (2006) Identification of chemically diverse Chkl inhibitors by receptor-based virtual screening. Bioorganic & Medicinal Chemistry 14: 4792-4802.
19. Klebe G (2006) Virtual ligand screening: strategies perspective and limitations. Drug Discovery Today 11: 580-594.
20. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) A guide to drug discovery: Hit and lead generation: beyond high-throughput screening. Nature Reviews Drug Discovery 2: 369-378. (Pubitemid 37361707)
21. Kitchen DB, Decornez H, Furr JR, and Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nature Reviews Drug Discovery 3: 925-949.
22. Seddon G, Lounnas V, McGuire R, van den Bergh T, Bywater RP, et al. (2012) Drug design for ever, from hype to hope. J Comput Aided Mol Des 26: 137-150.
23. Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, et al. (2005) Fragment-Based Lead Discovery Using X-ray Crystallography. J Med Chem 48: 403-413. (Pubitemid 40139783)
24. Carr R, Hann M (2002) The right road to drug discovery? Fragment-based screening casts doubt on the Lipinski route. Modern Drug Discov April, 45-48.
25. Davies NG, Browne H, Davis B, Drysdale MJ, Foloppe N, et al. (2012) Targeting conserved water molecules: Design of 4-aryl-5-cyanopyrrolo[2,3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based optimization. Bioorg Med Chem 20: 6770-6789.
26. Jeppsson F, Eketjall S, Janson J, Karlstrom S, Gustavsson S, et al. (2012) Discovery of AZD3839, a potent and selective BACE1 clinical candidate for the treatment of Alzheimers Disease. J Biol Chem Oct 9. [Epub ahead of print].
27. Knehans T, Schuller A, Doan DN, Nacro K, Hill J, et al. (2011) Structure-guided fragment-based in silico drug design of dengue protease inhibitors. J Comput Aided Mol Des 25: 263-274.
28. Erlanson DA (2012) Introduction to fragment-based drug discovery. Top Curr Chem 317: 1-32.
29. Foloppe N (2011) The benefits of constructing leads from fragment hits. Future Med Chem (2011) 3:1111-1115.
30. Chessari G, Woodhead AJ (2009) From fragment to clinical candidate - a historical perspective. Drug Discovery Today 14: 668-675.
31. Acharya C, Coop A, Polli JE, Mackerell AD Jr. (2011) Recent advances in ligand-based drug design: relevance and utility of the conformationally sampled pharmacophore approach. Curr Comput Aided Drug Des 7: 10-22.
32. Bursi R, Grootenhuis PD (1999) Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes. J Comput Aided Mol Des 13: 221-232. (Pubitemid 29145096)
33. Kubinyi H (2007) Hydrogen Bonding: The Last Mystery in Drug Design? In: Testa B, van de Waterbeemd H, Folkers G, Guy R, editors. Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. Verlag Helvetica Chimica Acta, Postfach, CH-8042 Zurich, Switzerland, pp. 513-524.
34. Kraljevic S, Stambrook PJ, Kresimir Pavelic K (2004) Accelerating drug discovery. EMBO Rep 5: 837-842.
35. Vyas V, Jain A, Jain A, Gupta A (2008) Virtual Screening: A Fast Tool for Drug Design. Sci Pharm 76: 333-360.
36. Cheng T, Li Q, Zhou Z, Wang Y, Bryant SH (2012) Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review. The AAPS Journal 14: 133-141.
37. Ripphausen P, Nisius B, Peltason L, Bajorath J (2010) Quo vadis, virtual screening? A comprehensive survey of prospective applications. J Med Chem 53: 8461-8467.
38. Vogt M, Stumpfe D, Geppert H, Bajorath J (2010) Scaffold hopping using two-dimensional fingerprints: true potential, black magic, or a hopeless endeavor? Guidelines for virtual screening. J Med Chem 53: 5707-5715.
39. Wolf A, Shahid M, Kasam V, Ziegler W, Hofmann-Apitius M (2010) In silico drug discovery approaches on grid computing infrastructures. Curr Clin Pharmacol 5: 37-46.
40. Fukunishi Y (2009) Structure-Based Drug Screening and Ligand-Based Drug Screening with Machine Learning. Combinatorial Chemistry & High Throughput Screening 12: 397-408.
41. Villoutreix BO, Eudes R, Miteva MA (2009) Structure-based virtual ligand screening: recent success stories. Comb Chem High Throughput Screen 12: 1000-1016.
42. Seifert MHJ, Martin L (2008) Essential Factors for Successful Virtual Screening. Mini Reviews in Medicinal Chemistry 8: 63-72. (Pubitemid 351320931)
43. Balakin KV, Kozintsev AV, Kiselyov AS, Savchuk NP (2006) Rational design approaches to chemical libraries for hit identification. Curr Drug Discov Technol 3: 49-65.
44. Wang J (2012) Challenges in Binding Free Energy Calculation Using MM-PB/GBSA. Bioenerg Open Access l:el02. Available: http://www.omicsgroup.org/ journals/2167-7662/2167-7662-l-elO2.php?aid=4747. Accessed 2013 Jan 25.
45. General IJ, Dragomirova R, Meirovitch H (2011) New Method for Calculating the Absolute Free Energy of Binding: The Effect of a Mobile Loop on the Avidin/Biotin Complex. J. Phys. Chem. B 115: 168-175.
46. Gu RX, Liu LA, Wei DQ, Du JG, Liu L, Liu H (2011) Free Energy Calculations on the Two Drug Binding Sites in the M2 Proton Channel. J Am Chem Soc 133: 10817-10825.
47. Malmstrom RD, Watowich SJ (2011) Using Free Energy of Binding Calculations To Improve the Accuracy of Virtual Screening Predictions J Chem Inf Model 51: 1648-1655.
48. Singh N, Warshel A. (2010) Absolute binding free energy calculations: on the accuracy of computational scoring of protein-ligand interactions. Protein 78: 1705-1723.
49. Fukunishi Y, Mitomo D, Nakamura H (2009) Protein-ligand binding free energy calculation by the smooth reaction path generation (SRPG) method. J Chem Info Model 49: 1944-1951.
50. Jiao D, Golubkov PA, Darden TA, Ren P (2008) Calculation of protein - ligand binding free energy by using a polarizable potential. PNAS 105: 6290-6295. (Pubitemid 351758339)
51. Wang J, Deng Y, Roux B (2006) Absolute Binding Free Energy Calculations Using Molecular Dynamics Simulations with Restraining Potentials. Biophysical Journal 91: 2798-2814. (Pubitemid 44526470)
52. Duff MR Jr., Grubbs J, Howell EE (2011) Isothermal Titration Calorimetry for Measuring Macromolecule-Ligand Affinity. J Vis Exp 55: e2796.
53. Chaires JB (2008) Calorimetry and Thermodynamics in Drug Design. Annu Rev Biophys 37: 135-151.
54. Englebienne P, Van Hoonacker Anne, Verhas M (2003) Surface plasmon resonance: principles, methods and applications in biomedical sciences. Spectroscopy 17: 255 - 273. (Pubitemid 36549487)
55. Ruvinsky AM (2007) Calculations of protein-ligand binding entropy of relative and overall molecular motions. J Comput Aided Mol Des 21: 361-370. (Pubitemid 47193846)
56. Chaplin M Water structure in science. http://www.lsbu.ac.uk/water/phobic. html. Accessed 2013 Jan 25.
57. Head Gordon T (1995) Is water structure around hydrophobic groups clathrate-like? Proc Nad Acad Sci USA 92: 8308-8312.
58. Butler JAV (1937) The energy and entropy of hydration of organic compounds. Trans Faraday Soc 33: 229-238.
59. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM (2003) The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3: 1125-1154.
60. Chodera JD, Mobley DL (2013) Entropy-Enthalpy Compensation: Role and Ramifications in Biomolecular Ligand Recognition and Design. Annual Review of Biophysics 42: (Volume publication date June 2013
61. Roy S, Bagchi B (2012) Free Energy Barriers for Escape of Water Molecules from Protein Hydration Layer The journal of Physical Chemistry. J Phys Chem B 116: 2958-68.
62. Ritschel T, Philipp C, Kohler PC, Neudert G, Heine A, et al. (2009) How to Replace the Residual Solvation Shell of Polar Active Site Residues to Achieve Nanomolar Inhibition of tRNA-Guanine Transglycosylase. ChemMedChem 4: 2012 - 2023.
63. Kadirvelraj R, Foley BL, DyekJEer JD, Woods RJ (2008) Involvement of Water in Carbohydrate-Protein Binding: Concanavalin A Revisited. J Am Chem Soc 130: 16933-16942.
64. Li Z, Lazaridis T (2007) Water at biomolecular binding interfaces. Phys Chem Chem Phys 9: 573-581.
65. Nguyen CN, Kurtzman Young T, Gilson MK (2012) Grid inhomogeneous solvation theory: Hydration structure and thermodynamics of the miniature receptor cucurbit [7] uril. J Chem Phys 137: 044-101.
66. Ross GA, Morris GM, Biggin PC (2012) Rapid and Accurate Prediction and Scoring of Water Molecules in Protein Binding Sites. PLoS ONE 7: e32036.
67. Water.where it matters, when it matters. Available: http://www.eyesopen. com/SZMAP. Accessed 2013 Jan 25.
68. A new paradigm in ligand optimization. Available: http://www.schrodinger. com/WaterMap.php. Accessed 2013 Jan 25.
69. Genheden S, Luchko T, Gusarov S, Kovalenko A, Ryde U (2010) An MM/3D-RISM Approach for Ligand Binding Affinities. J Phys Chem 114: 8505-8516.
70. Genheden S, Mikulskis P, Hu L, Kongsted J, Soderhjelm P, Ryde U (2011) Accurate Predictions of Nonpolar Solvation Free Energies Require Explicit Consideration of Binding-Site Hydration. J Am Chem Soc 133: 13081-13092.
71. Ben-Nairn A (1990) Solvent effects on protein association and protein folding. Biopolymers 29: 567 - 596.
72. Li Z, Lazaridis T (2006) Thermodynamics of buried water clusters at a protein at ligand binding interface. J Phys Chem B 110: 1464-1475.
73. Li Z, Lazaridis T (2005) The effect of water displacement on binding thermodynamics: concanavalin A. J Phys Chem B 109: 662-670. (Pubitemid 40121013)
74. Kohler PC, Ritschel T, Schweizer WB, Klebe G, Diederich F (2009) High-Affinity Inhibitors of tRNA-Guanine Transglycosylase Replacing the Function of a Structural Water Cluster. Chemistry 15: 10809-10817.
75. Stengl B, Meyer E, Heine A, Brenk R, Diederich F, et al. (2007) Crystal Structures of tRNA-guanine Transglycosylase (TGT) in Complex with Novel and Potent Inhibitors Unravel Pronounced Induced-fit Adaptations and Suggest Dimer Formation Upon Substrate Binding. J Mol Biol 370: 492-511. (Pubitemid 46898428)
76. Chakravarty S, Ghersi D, Sanchez R (2011) Systematic assessment of accuracy of comparative model of proteins belonging to different structural fold classes. J Mol Model 17:2831-2837.
77. Zhang Y (2008) Progress and challenges in protein structure prediction. Curr Opin Struct Biol 18: 342-348.
78. Krieger E, Joo K, Lee J, Lee J, Raman S, et al. (2009) Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins 77: 114-122.
79. Venselaar H, Joosten RP, Vroling B, Baakman CAB, Hekkelman ML, et al. (2010) Homology modelling and spectroscopy, a never-ending love story. Eur Biophys J 39: 551-563.
80. Brooijmans N, Chang YW, Mobilio D, Denny RA, Humblet C (2010) An enriched structural kinase database to enable kinome-wide structure-based analyses and drug discovery. Protein Sci 19: 763-774.
81. Knight JDR, Qian B, Baker D, Kothary R (2007) Conservation, Variability and the Modeling of Active Protein Kinases. PLoS ONE 2: e982.
82. Protein Data Bank (2011) http://www.pdb.org. Accessed 2013 Jan 25.
83. Lundstrom K (2009) An overview on GPCRs and drug discovery: structure-based drug design and structural biology on GPCRs. Methods Mol Biol 552: 51-66.
84. Franceschi F, Duffy EM (2006) Structure-based drug design meets the ribosome. Biochem Pharmacol 71: 1016-1025.
85. Todd AE, Marsden RL, Thornton JM, Orengo CA (2005) Progress of structural genomics initiatives: an analysis of solved target structures. J Mol Biol 348: 1235-1260.
86. Janzen WP, Hull-Ryde A (2011) Kinases as Targets for Drug Discovery in an Academic Setting. International Drug Discovery. Available: www. internationaldrugdiscovery.com/images/article/l-Janzen.pdf. Accessed 2013 Jan 25.
87. Chico LK, Van Eldik LJ, Watterson DM (2009) Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 8: 892-909.
88. Catapano LA, Manji HK (2008) Kinases as drug targets in the treatment of bipolar disorder. Drug Disc Today 13: 295-302.
89. Zhang J, Yang PL, Gray NS. (2009) Targeting cancer with small molecule kinase inhibitors. Nature Rev Cancer 9: 28 - 39.
90. Overington J (2010) Kinase inhibitor patents over time. Available: http://chembl.blogspot.nl/2010/03/kinase-inhibitor-patents-over-time.html. Accessed 2013 Jan 25.
91. Suhrer SJ, Markus Wiederstein M, Sippl MJ (2007) QSCOP - SCOP quantified by structural relationships. Bioinformatics Application Note. 23: 513-514. (Pubitemid 46323140)
92. Scheeff ED, Bourne PE (2005) Structural Evolution of the Protein Kinase-Like Superfamily. PLoS Comput Biol 5: e49.
93. Hanks SK, Hunter T. (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9: 576-596.
94. Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T, et al. (2012) Visualization and Measurement of ATP Levels in Living Cells Replicating Hepatitis C Virus Genome RNA. PLoS Pathog 3: el002561.
95. Bywater RP (2012) Protein folding: a problem with multiple solutions. J Biomol Struct Dyn Aug 7. [Epub ahead of print]
96. Marcheler-Bauer A, Panchenko AR, Ariel N, Bryant S (2002) Comparison of sequence and structure alignments for protein domains. Proteins 48: 439-446. (Pubitemid 34810410)
97. Panchenko AR, Bryant S (2002) A comparison of Position-Specific Score Matrices based on sequence and structure alignments. Protein Science 11: 361-370. (Pubitemid 34075799)
98. Toomula N, Kumar DS, Kumar AP (2011) Computational Methods for Protein Structure Prediction and Its Application in Drug Design. J Proteomics Bioinform 4: 289-293.
99. Faure G, Aurelie Bornot A, de Brevern AG (2008) Protein contacts, inter-residue interactions and side-chain Modelling. Biochimie 90: 626-639.
100. Hartmann C, Antes I, Lengauer T (2007) IRECS: A new algorithm for the selection of most probable ensembles of side-chain conformations in protein models. Protein Sci 16: 1294-1307. (Pubitemid 46984864)
101. Kannan N, and Andrew F, Neuwald AF (2004) Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2a. Protein Sci 13: 2059-2077. (Pubitemid 38989612)
102. Sheinerman FB, Giraud E, Laoui A. (2005) High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding. J Mol Biol 352: 1134-1156. (Pubitemid 41316721)
103. Caballero J, Quiliano M, Alzate-Morales JH, Zimic M, Deharo E (2011) Docking and quantitative structure - activity relationship studies for 3-fluoro-4-(pyrrolo[2,l-fJ[l,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(lH- pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fiuorophenoxy)-2- pyridinylamine derivatives as c-Met kinase inhibitors. J Comput Aided Mol Des 25: 349-369.
104. Repasky MP, Murphy RB, Banks JL, GreenwoodJR, Tubert-Brohman I, et al. (2012) Docking performance of the glide program as evaluated on the Astex and DUD datasets: a complete set of glide SP results and selected results for a new scoring function integrating WaterMap and glide. J Comput Aided Mol Des 26: 787-799.
105. Spitzer R, Jain AN (2012) Surflex-Dock: Docking benchmarks 125. and real-world application. J Comput Aided Mol Des 26: 687 - 699. 126.
106. Taylor RD, Jewsbury PJ, Essex JW (2002) A review of protein-small molecule docking methods. J Comput Aided Mol Des 16: 151-166. 127.
107. Kulkarni RG, Srivani P, Achaiah G, Sastry GN (2007) Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study J Comput Aided Mol Des 21: 155 - 166. 128. (Pubitemid 46510841)
108. Assefa H, Kamath S, Buolamwini JK (2003) 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase 129. inhibitors. J Comput Aided Mol Des 17: 475-493. (Pubitemid 38008961)
109. Nicklaus MC, Milne GW, Burke TR Jr. (1992) QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors. J Comput Aided Mol 130. Des 6: 487-504.
110. Pollack SJ, Beyer KS, Lock C, Muller I, Sheppard D, et al. (2011) A comparative study of fragment screening methods on the p38a 131. kinase: new methods, new insights. J Comput Aided Mol Des 25: 677-687.
111. Foloppe N, Fisher LM, Howes R, Kierstan P, Potter A, et al. Structure-Based Design of Novel Chkl Inhibitors: Insights 132. into Hydrogen Bonding and Protein-Ligand Affinity. J Med Chem 48: 4332-4345.
112. Chema D, Eren D, Yayon A, Goldblum A, Zaliani A (2004) Identifying the binding mode of a molecular scaffold. J Comput 133. Aided Mol Des 18: 23-40. (Pubitemid 39127588)
113. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996. (Pubitemid 44835126)
114. Paiva AC, Oliveira L, Horn F, Bywater RP, Vriend G. (2006) 134. Modeling GPCRs. Ernst Schering Found Symp Proc. 2: 23-47.
115. Oliveira L, Hulsen T, Lutje Hulsik D, Paiva ACM, Vriend G (2004) Heavier-than-air flying machines are impossible. FEBS 135.
116. Letters 564: 269-273.
117. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. Crystal structure of the P2 adrenergic receptor-Gs protein 136. complex. Nature 477: 549-555.
118. Kobilka BK, Deupi X (2007) Conformational complexity of G-protein-coupled receptors. Trends Pharmacol Sci 28: 397 - 406. (Pubitemid 47087966
119. Wichard JD, ter Laak A, Krause G, Heinrich N, Kiihne R, et al. 137. (2011) Chemogenomic Analysis of G-Protein Coupled Receptors and Their Ligands Deciphers Locks and Keys Governing Diverse Aspects of Signalling. PLoS ONE 6: el6811.
120. Smith SO (2010) Structure and Activation of the Visual Pigment 138. Rhodopsin. Annu Rev Biophys 39: 309-328.
121. Provasi D, Artacho MC, Negri A, Mobarec JC, Filizola M (2011) Ligand-Induced Modulation of the Free-Energy Landscape of G Protein-Coupled Receptors Explored by Adaptive Biasing 139. Techniques. PLoS Comput Biol 7: el002193.
122. Ye S, Zaitseva E, Caltabiano G, Schertler GFX, Sakmar TP, et al. Tracking G-protein-coupled receptor activation using genetically 140. encoded infrared probes. Nature 464: 1386-1389.
123. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krau N, et al. Crystal structure of opsin in its G-protein-interacting 141. conformation. Nature 455: 497-502.
124. Deupi X, Kobilka B (2007) Activation of G Protein-coupled receptors. Advances in protein chemist 74: 137-166. (Pubitemid 47369749)
125. Rubenstein LA, Lanzara RG (1998) Activation of G protein- 142. coupled receptors entails cysteine modulation of agonist binding. Journal of Molecular Structure (Theochem) 430: 57-71. (Pubitemid 128388608)
126. Ahuja S, Smith SO (2009) Multiple switches in G protein-coupled receptor activation. Trends Pharmacol Sci 30: 494 - 502.
127. Hofmann KP, Scheerer P, Hildebrand PW, Choe HW, Park JH, et al. (2009) A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem Sci 34: 540-552.
128. Bywater RP (2005) Location and nature of the residues important for ligand recognition in G Protein-coupled receptors. J Mol Recognit 18: 60-72. (Pubitemid 40059571)
129. Oliveira L, Paiva PB, Paiva AC, Vriend G (2003) Identification of functionally conserved residues with the use of entropy-variability plots. Proteins 52: 544-552. (Pubitemid 37034152)
130. Sanders MPA, Fleuren WWM, Verhoeven S, van den Beld S, Alkema W, et al. (2011) ss-TEA: Entropy based identification of receptor specific ligand binding residues from a multiple sequence alignment of class A GPCRs BMC Bioinformatics 12: 332-341.
131. Rasmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, et al. (2007) Crystal structure of the human b2 adrenergic G-protein-coupled receptor. Nature 450: 383-387. (Pubitemid 350126755)
132. Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, et al. (2008) Virtual Screen for Diverse Ligands: Discovery of Selective G Protein-Coupled Receptor Antagonists. J Am Chem Soc 130.-5115-5123. (Pubitemid 351537071)
133. Vilar S, Ferino G, Phatak SS, Berk B, Cavasotto CN, Costanzi S (2011) Docking-based virtual screening for ligands of G protein-coupled receptors: not only crystal structures but also in silico models. J Mol Graph Model 29: 614-623.
134. Wacker D, Fenalti G, Brown MA, Katritch V, Abagayan R, et al. (2010) Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc 132: 11443-11445
135. Katritch V, Abagyan R (2012) GPCR agonist binding revealed by modeling and crystallography. Trends in Pharmacological Sciences 37: 343-352.
136. Kobilka B, Schertler GF (2008) New G-protein-coupled receptor crystal structures: insights and limitations. Trends Pharmacol Sci 29: 79-83.
137. Michino M, Abola E, Brooks CL, Dixon JS, Moult J, et al. (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8: 455-463.
138. Perez-Aguilar JM, Saven JG, Liu R (2012) Human p. Opioid Receptor Models with Evaluation of the Accuracy Using the Crystal Structure of the Murine |X Opioid Receptor. J Anesth Clin Res 3:6.
139. Worth CL, Kreuchwig A, Gunnar Kleinau G, Krause G (2011) GPCR-SSFE: A comprehensive database of G-protein-coupled receptor template predictions and homology models. BMC Bioinformatics 12: 185.
140. Topiol S, Sabio M (2009) X-ray structure breakthroughs in the GPCR transmembrane region. Biochem Pharmacol 2009 78: 11-20.
141. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G (2003) GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res 31: 294-297. (Pubitemid 36150388)
142. Costanzi S, Tikhonova IG, Harden TK, Jacobson KA (2009) Ligand and structure-based methodologies for the prediction of the activity of G protein-coupled receptor ligands. J Comput Aided Mol Des 23: 747-754.
143. Foloppe N, Benwell K, Brooks TD, Kennett G, Knight AR, et al. (2009) Discovery and functional evaluation of diverse novel human CB1 receptor ligands. Bioorganic & Medicinal Chemistry Letters 19:4183-4190.
144. Poulsen A, Bjornholm B, Gundertofte K, Pogozheva ID, Liljefors T (2003) Pharmacophore and receptor models for neurokinin receptors. J Comput Aided Mol Des 11: 765-783. (Pubitemid 38418288)
145. Launay G, Teletchea S, Wade F, Pajot-Augy E, Gibrat JF, Sanz G (2012) Automatic modeling of mammalian olfactory receptors and docking of odorants. Protein Eng Des Sel 25: 377-386.
146. Jain V, Saravanan P, Arvind A, Mohan CG (2011) First pharmacophore model of CCR3 receptor antagonists and its homology model-assisted, stepwise virtual screening. Chem Biol Drug Des 77: 373-387.
147. Tebben AJ, Schnur DM (2011) Beyond rhodopsin: G protein-coupled receptor structure and modeling incorporating the beta2-adrenergic and adenosine A(2A) crystal structures. Methods Mol Biol 672: 359-386.
148. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, et al. (2009) Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 Receptors. PLoS ONE 4: e8084.
149. Costanzi S (2008) On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. J Med Chem 51: 2907-2914. (Pubitemid 351706019)
150. Radestock S, Weil T, Renner S (2008) Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring. J Chem Inf Model 48:1104-1117.
151. Chen JZ, Wang J, Xie XQ (2007) GPCR structure-based virtual screening approach for CB2 antagonist search. J Chem Inf Model 2007 47: 1626-1637. (Pubitemid 47210066)
152. Schlegel B, Laggner C, Meier R, Langer T, Schnell D, et al. (2007) Generation of a homology model of the human histamine H3 receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des 21: 437-453. (Pubitemid 47423277)
153. Singh N, Cheve G, Ferguson DM, McCurdy CR (2006) A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist. J Comput Aided Mol Des 20: 471-493. (Pubitemid 44823885)
154. Bissantz C, Bernard P, Hibert M, Rognan D. (2003) Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins 50: 5-25. (Pubitemid 36090604)
155. Broer BM, Gurrathet M, Holtje HD (2003) Molecular modeling studies on the ORL1-receptor and ORL1-agonists J Comput Aided Mol Des 17: 739-754. (Pubitemid 38418286)
156. Sanders MP, Verhoeven S, De Graaf C, Roumen L, Vroling B, et al. (2011) Snooker: a structure-based pharmacophore generation tool applied to class A GPCRs. J Chem Inf Model 51: 2277-2292.
157. Sanders MPA, Roumen L, van der Horst E, Lane JR, Vischer HF, et al. (2012) A Prospective Cross-Screening Study on G-Protein-Coupled Receptors: Lessons Learned in Virtual Compound Library Design. J Med Chem 55: 5311-5325.
158. Levit A, Barak D, Behrens M, Meyerhof W, Niv MY (2012) Homology Model-Assisted Elucidation of Binding Sites in GPCRs. Methods Mol Biol. 914:179-205.
159. Roumen L, Sanders MPA, Bas Vroling B, de Esch IJP, Jacob de Vlieg, et al. (2011) In Silico Veritas: The Pitfalls and Challenges of Predicting GPCR-Ligand Interactions. Pharmaceuticals 4: 1196-1215.
160. Beddell CR, Goodford PJ, Norrington FE, Wilkinson S, Wootton R (1976) Compounds designed to fit a site of known structure in human haemoglobin. Br J Pharmacol 57: 201 - 209.
161. Silverman E (2012) Sanofi CEAO: Who needs Big Pharma Scientists? Available: http://www.pharmalot.com/2012/03/sanofi-ceo-who-needs-big-pharma- scientists/. Accessed 2013 Jan 25.
162. Santoro MA (2006) Charting a Sustainable Path for the Twenty-First Century Pharmaceutical Industry. In: Santoro MA and Gorrie TM, editors. Ethics and the Pharmaceutical Industry. Cambridge University Press, pp. 1-9.